Gilead earnings: $3.32 per share, vs expected EPS of $3

Analysts expected Gilead to report earnings of about $3 a share on $8.14 billion in revenue, according to a consensus estimate from Thomson Reuters.. Gilead boasts a market share of more than 90 percent of all hepatitis C treatments with its two highest-grossing products, Harvoni and Sovaldi, the company said on a conference call last year. A full course of...